Jerry Kunkel
Psychiatric/Mental Health · London, KYNPI 1548781164
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by AbbVie at 58.9% of the total. 2025 is the largest year on record at $5,794, more than ten times the $353 reported in 2021. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 376 payments — averaging $33.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$863
- Vanda Pharmaceuticals Inc.$566
- Neurocrine Biosciences, Inc.$561
- Axsome Therapeutics, Inc.$344
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$6,10048%
- Travel & lodging$2022%
- Food & beverage$6,41850%
- Education$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 81 | $7,521 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 82 | $1,188 |
| Otsuka America Pharmaceutical, Inc. | 53 | $863 |
| Vanda Pharmaceuticals Inc. | 27 | $566 |
| Neurocrine Biosciences, Inc. | 22 | $561 |
| Axsome Therapeutics, Inc. | 13 | $344 |
| Lundbeck LLC | 20 | $324 |
| Teva Pharmaceuticals USA, Inc. | 14 | $231 |
| Novo Nordisk | 11 | $187 |
| Ironshore Pharmaceuticals Inc. | 10 | $169 |
| Lilly USA, LLC | 9 | $149 |
| Supernus Pharmaceuticals, Inc. | 8 | $135 |
| Alkermes, Inc. | 6 | $130 |
| Johnson & Johnson | 3 | $108 |
| Avanir Pharmaceuticals, Inc. | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $39 |
| Almatica Pharma LLC | 2 | $38 |
| Medtronic | 1 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Biogen | 1 | $27 |
| Collegium Pharmaceutical, Inc. | 1 | $25 |
| Corcept Therapeutics | 1 | $16 |
| Merck | 1 | $15 |
| GSK | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,778 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 117 | $177,245 |
| AustedoDeutetrabenazine | 28 | $172,230 |
| IngrezzaValbenazine Tosylate | 14 | $114,969 |
| RexultiBrexpiprazole | 45 | $64,357 |
| TrintellixVortioxetine Hydrobromide | 21 | $13,655 |
| QuviviqDaridorexant Hcl | 13 | $6,353 |
| Jornay PmMethylphenidate Hcl | 12 | $5,340 |
| Vilazodone Hcl | 45 | $2,516 |
| Adderall XrDextroamphetamine/Amphetamine | 11 | $2,213 |
| Prazosin Hcl | 96 | $2,192 |
| Aripiprazole | 26 | $2,043 |
| Buspirone Hcl | 146 | $1,849 |
| Hydroxyzine Hcl | 147 | $1,337 |
| Duloxetine Hcl | 86 | $1,128 |
| Doxepin Hcl | 32 | $1,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $7,521 | $177,245117 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $231 | $172,23028 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $561 | $114,96914 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $863 | $64,35745 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $39 | $13,65521 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $28 | $6,35313 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $169 | $5,34012 claims |
| Almatica Pharma LLCSertraline Hcl | $38 | $13740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in London
- Tammy WhiteheadLondon$19K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
- Davika MattoxMorehead$79K
- Molly LutzCrestview Hills$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.